Annette Hasenburg Prof., Dr, med
Director, Obstetrics and Gynecology, Mainz University Medical Center, Mainz, GermanyDr. Annette Hasenburg is the Director of Obstetrics and Gynecology at Mainz University Medical Center in Mainz, Germany. She is Head of the ESGO (European Society of Gynaecologic Oncology) Task Force Psycho-Oncology and is on the board of directors of the Institute of Sexuality and Health of the University Freiburg in Freiburg, Germany.
Dr. Hasenburg received her medical degree from Ruhr-University, Bochum, Germany, where she also received residency training in internal medicine (Evangelisches Krankenhaus Herne) and obstetrics and gynecology (Marienhospital Herne). She received specialist training and qualification in psychotherapy at the Institute of Psychotherapy and Psychosomatic Medicine in Düsseldorf. She completed a postdoctoral fellowship in the Department of Obstetrics and Gynecology, Oncology Division, at Baylor College of Medicine in Houston, Texas.
Since 2018, Dr. Hasenburg has been on the Board of Directors of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) and since 2020 on the Board of Directors of the DGGG (Deutsche Gesellschaft Gynäkologie und Geburtshilfe).
Disclosures
- Honoraria: AstraZeneca; Celgen; GSK; LEO Pharma; MedConcept GmbH; Med update GmbH; Medicultus; Pfizer; Promedicis GmbH; Softconsult; Roche Pharma AG; Streamedup! GmbH; Tesaro Bio Germany GmbH
- Advisory roles: AstraZeneca; GSK; LEO Pharma; PharmaMar; Promedicis GmbH; Roche Pharma AG; Tesaro Bio Germany GmbH; MSD (Merck Sharp & Dohme) GmbH
Recent Contributions to PracticeUpdate:
- ESMO 2024: Recommendations From Dr. Annette Hasenburg for Gynecological Cancer
- Atezolizumab and Chemotherapy for Advanced or Recurrent Endometrial Cancer
- Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
- Simple vs Radical Hysterectomy in Women With Low-Risk Cervical Cancer
- Neoadjuvant Chemotherapy Plus Camrelizumab for Locally Advanced Cervical Cancer
- Atezolizumab Plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer
- ESMO 2023: Recommendations From Dr. Annette Hasenburg for Gynecological Cancer
- ASCO 2023: Abstract Recommendations From Prof. Dr. Annette Hasenburg for Gynecologic Oncology
- 2022 Top Story in Oncology: Results From the Phase II KEYNOTE-158 Study
- Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone for Platinum-Resistant Recurrent Ovarian Cancer